XTENT Announces 2007 Financial Results(n October -- Completed enrollment of ...),Health

-- Completed enrollment of the CUSTOM III clinical trial

-- Introduced design enhancements to the Custom NX DES system to allow for

greater ease-of-use by clinicians

-- Submitted an IDE application to the FDA to initiate its CUSTOM IV

clinical trial

-- Submitted the design dossier for CE Mark

-- Expanded its Menlo Park, California facilities to prepare for

manufacturing ramp-up

Conference Call and Webcast Information

The company will hold a conference call today at 2 p.m., Pacific Time (5 p.m. Eastern Time). The call will be hosted by Gregory D. Casciaro, XTENT's President and Chief Executive Officer, and Tim Kahlenberg, Chief Financial Officer.

The teleconference can be accessed via the investor relations section of the Company's website at http://investor.xtentinc.com/events.cfm or by calling 877 627-6580 (domestic), 719 325-4903 (international). Please dial in or access the website 5 to 10 minutes prior to the beginning of the call.

An online archive of the webcast will be available for a minimum of three months by accessing the investor relations portion of the company's website at http://investor.xtentinc.com.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device. Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.